Assertio Shares Climb Following Revenue Surprise
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 10 2025
0mins
Source: SeekingAlpha
Quarterly Revenue Growth: Assertio (ASRT) reported a 69.4% increase in third quarter revenue, reaching $49.46M, exceeding analysts' expectations by $22.44M, driven by strong demand and significant orders for Rolvedon.
Stock Performance: Following the revenue report, Assertio's stock rose approximately 7% in after-hours trading.
Revised Financial Forecast: The company adjusted its full-year net product sales forecast to $110M to $112M, down from $108M to $118M, and updated its adjusted EBITDA forecast to $14M to $16M.
Leadership Change: Assertio promoted Paul Schwichtenberg to the newly created position of President and Chief Operating Officer.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ASRT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ASRT
Wall Street analysts forecast ASRT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASRT is 27.67 USD with a low forecast of 3.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 11.730
Low
3.00
Averages
27.67
High
45.00
Current: 11.730
Low
3.00
Averages
27.67
High
45.00
About ASRT
Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Healthcare Stocks with Strong Earnings Momentum Earn A+ EPS Revision Grades
- Investor Attention: As the earnings season unfolds, mid to low market capitalization healthcare stocks are drawing investor attention due to their strong earnings momentum, indicating growing market confidence in this sector.
- Analyst Expectations: The EPS Revision Grade reflects the trend in analyst earnings estimates, with A+ ratings indicating optimistic projections for future performance, potentially driving stock prices higher.
- List of A+ Rated Stocks: Currently, companies such as Aldeyra Therapeutics, Altimmune, Annovis Bio, and Assertio Holdings have received A+ EPS Revision Grades, showcasing their strong performance in the eyes of analysts.
- Market Strategy Impact: These A+ rated healthcare stocks are likely to attract more investor interest, potentially triggering positive sentiment towards the healthcare sector as a whole, thereby enhancing the performance of related ETFs.
Continue Reading
Assertio Holdings Regains Nasdaq Compliance with Minimum Bid Price Rule
- Compliance Regained: Assertio Holdings announced that as of January 12, 2026, it has successfully regained compliance with Nasdaq listing requirements by maintaining a minimum bid price of $1.00 per share for ten consecutive days, marking a significant achievement in capital allocation flexibility.
- Successful Reverse Split: The company effectively increased its stock price through a reverse stock split completed in December 2025, ensuring compliance restoration efficiently, which not only boosts market confidence but also provides greater flexibility for future capital operations.
- CEO Statement: CEO Mark Reisenauer expressed satisfaction with the regained compliance, emphasizing that this achievement lays a foundation for the company's future growth and demonstrates Assertio's ongoing competitiveness in the pharmaceutical market.
- Company Background: Assertio is a pharmaceutical company focused on oncology, neurology, and pain management, dedicated to offering differentiated products designed to meet patient needs, and will continue to drive innovation to support patient health.
Continue Reading